Safety pharmacology identify potential adverse effects in drug candidates early in the drug development pipeline, contributing to reduces the overall cost of the drug-discovery phase. Faster, cheaper and more reliable assays based on zebrafish are being developed as major tools for assessing toxicity of chemicals during the drug-discovery process.
Acute Toxicity Assay
The analysis of the subject allows to determine short- and medium-term (7 days) toxicity using zebrafish embryos in the early stages of their development. The test uses the LD50 (lethal dose 50) to determine the potential safety or toxicity of the compounds.
Chronic toxicity Assay
This assay allows us to calculate the no-observed-effect-concentration (NOEC) and the lowest-observed-effect-concentration (LOEC). Furthermore, Ikan conducts long-term studies on the effect of target compound in reproducing adults and in the new progeny development, analysing the teratogenicity among other variables.
One not of the most relevant trials that are carried out for the evaluation of the safety of drugs consisting in observing the effect they cause on cardiac function. Ikan carries out cardiotoxicity assays to evaluate the potential cardiotoxicty of drugs by observing zebrafish’s ECG patterns which are similar to the ECG of humans.
This service is complementary to the Acute Toxicity test. It permits the assessment of potential drug-induced liver injuries (DILI) that is one of the main reasons for rejection by the FDA.
The use of zebrafish as a toxicity model in developmental neurotoxicity screening offers the opportunity to research working mechanism of drugs.